Education
About Us
Working with TipRanks
Follow Us
Innoviva Inc (INVA)
NASDAQ:INVA
Top Page
Innoviva
(NASDAQ:INVA)
66Neutral
Innoviva (INVA) vs. S&P 500 (SPY)
Market Cap
$1.10B
Dividend YieldN/A
Average Volume (3M)665.75K
Price to Earnings (P/E)83.2
Beta (1Y)0.50
Revenue Growth14.88%
EPS Growth-86.70%
CountryUS
Employees112
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)0.21
Shares Outstanding62,675,545
10 Day Avg. Volume1,125,092
30 Day Avg. Volume665,755
Financial Highlights & Ratios
PEG Ratio1.12
Price to Book (P/B)N/A
Price to Sales (P/S)3.08
Price to Cash Flow (P/CF)4.70
P/FCF Ratio4.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$55.00Price Target Upside216.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Innoviva Business Overview & Revenue Model
Company DescriptionInnoviva, Inc. is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.
How the Company Makes MoneyInnoviva generates revenue primarily through royalty payments derived from its collaborations with pharmaceutical partners. The company holds economic interests in the royalties tied to certain healthcare products, particularly in the respiratory medicine space. A significant portion of Innoviva's income is derived from its partnership with GlaxoSmithKline (GSK), through which it receives royalties on sales of products like RELVAR/BREO ELLIPTA and ANORO ELLIPTA. The company's earnings are heavily influenced by the commercial success and market penetration of these products, as well as its strategic management of its royalty portfolio.
Innoviva Financial Statement Overview
Summary
Innoviva shows strong financial health with a high balance sheet score of 82 and cash flow score of 85, indicating robust cash generation and low leverage. The income statement score is slightly lower at 77 due to a drop in net profit margin and missing EBITDA data. Overall, the company has consistent revenue growth and a solid equity base.Income Statement
Innoviva's income statement shows a strong gross profit margin of 100% for 2024, indicating effective cost management. Net profit margin decreased to 6.5% from the previous year's 57.9%, primarily due to a significant reduction in net income. Revenue grew by 15.5% from 2023 to 2024, reflecting positive growth trajectory. However, the lack of EBITDA data for 2024 weakens the analysis.77
Positive
Balance Sheet
Innoviva's balance sheet is strong with a debt-to-equity ratio of 0.28, showcasing low leverage and financial stability. The equity ratio stands at 53.1% in 2024, affirming a solid equity base. Return on equity (ROE) has decreased to 3.4% in 2024 from 26.6% in 2023, indicating reduced profitability.82
Very Positive
Cash Flow
Cash flow analysis reveals a robust free cash flow growth of 33.9% from 2023 to 2024, highlighting strong cash generation capabilities. The operating cash flow to net income ratio is high at 8.1, indicating efficient operations. However, the free cash flow to net income ratio is very high at 8.1, suggesting potential reinvestment challenges.85
Very Positive
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 358.71M | 310.46M | 331.34M | 391.87M | 336.79M | Gross Profit |
| 358.71M | 261.06M | 317.55M | 378.03M | 335.01M | EBIT |
| 229.37M | 176.71M | 209.99M | 375.10M | 321.12M | EBITDA |
| 85.50M | 248.96M | 322.25M | 478.18M | 386.42M | Net Income Common Stockholders |
| 23.39M | 179.72M | 213.92M | 368.84M | 224.40M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 304.96M | 193.51M | 291.05M | 201.53M | 246.49M | Total Assets |
| 1.30B | 1.24B | 1.23B | 926.39M | 999.57M | Total Debt |
| 192.03M | 449.08M | 637.88M | 394.65M | 385.52M | Net Debt |
| -112.94M | 255.56M | 346.83M | 193.13M | 139.03M | Total Liabilities |
| 609.90M | 568.55M | 665.71M | 400.46M | 391.73M | Stockholders Equity |
| 691.16M | 674.96M | 565.79M | 414.74M | 539.91M |
| Cash Flow | Free Cash Flow | |||
| 188.42M | 140.65M | 201.66M | 362.51M | 313.10M | Operating Cash Flow |
| 188.69M | 141.06M | 201.73M | 363.81M | 313.11M | Investing Cash Flow |
| -63.79M | -66.76M | -56.63M | 43.72M | -314.94M | Financing Cash Flow |
| -13.45M | -171.84M | -55.57M | -452.50M | -29.79M |
Innoviva Technical Analysis
Negative
17.39
Price Trends
18.00
Negative
18.60
Negative
18.28
Negative
Market Momentum
-0.19
Positive
36.67
Neutral
13.58
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INVA, the sentiment is Negative. The current price of 17.39 is below the 20-day moving average (MA) of 17.83, below the 50-day MA of 18.00, and below the 200-day MA of 18.28, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 36.67 is Neutral, neither overbought nor oversold. The STOCH value of 13.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INVA.
Innoviva Risk Analysis
Innoviva disclosed 75 risk factors in its most recent earnings report. Innoviva reported the most risks in the “Legal & Regulatory” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Innoviva Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $18.94B | 17.18 | 12.75% | 2.59% | -3.85% | -24.34% | |
75 Outperform | $142.50B | 306.43 | 2.28% | 2.70% | 6.16% | -91.54% | |
71 Outperform | $239.29B | 14.06 | 40.81% | 3.34% | 6.85% | 4577.79% | |
71 Outperform | $377.06B | 89.36 | 61.94% | 2.97% | 3.71% | -12.14% | |
66 Neutral | $1.10B | 83.22 | 3.42% | ― | 14.88% | -86.70% | |
64 Neutral | $125.40B | ― | -3.15% | ― | 11.64% | -114.72% | |
49 Neutral | $6.84B | 0.05 | -53.14% | 2.48% | 24.49% | -3.26% |
* Healthcare Sector Average
Performance Comparison
INVA
Innoviva
17.39
2.67
18.14%
GILD
Gilead Sciences
113.35
41.32
57.36%
MRK
Merck & Company
94.71
-23.34
-19.77%
VRTX
Vertex Pharmaceuticals
502.92
94.15
23.03%
ABBV
AbbVie
211.55
36.72
21.00%
RPRX
Royalty Pharma
32.68
3.71
12.81%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.